-

Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET.

The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

Contacts

Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Release Versions

Contacts

Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com

More News From Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease...

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results...

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering...
Back to Newsroom